OrganiGram's stock rises as Canadian pot company's revenue tops analyst estimate
By Steve Gelsi
OrganiGram makes inroads into the European market through a minority stake in Germany's Sanity Group
OrganiGram Holdings Inc.'s stock was up by 23% on Wednesday after the Canadian cannabis producer turned a profit and reported better-than-expected revenue.
The stock is on pace for its largest percent increase since March 11, 2021, when it rose about 39.8%, according to Dow Jones Market Data.
Toronto-based OrganiGram (OGI) (CA:OGI) swung to third-quarter net income of C$2.82 million ($2.05 million), from a loss of C$213.45 million in the year-ago quarter.
Net revenue increased by 25% to C$41.06 million, well ahead of the FactSet consensus estimate of C$39.4 million.
The company said its results were strong and that it has made inroads into the European market with a minority stake in Germany's Sanity Group GmbH.
OrganiGram and British American Tobacco (UK:BATS) continue to work together through a product-development agreement on edibles, vape and beverage businesses, as well as "new disruptive inhalation formats," the company said.
Organigram's stock rose 33 cents to $1.77 a share. The stock is on pace for its largest percent increase since March 11, 2021, when it rose about 39.8%.
Prior to Tuesday's moves, OrganiGram's stock has risen 9.9% in 2024.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-13-24 1416ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
Morningstar’s Guide to Investing in Stocks
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst